MENK published in PubMed

"In vivo study the activated CD4+, CD8+ T cells and decreased ability to induce differentiation of Foxp3+ regulatory T cells were detected post treatment of MENK. Thus, it is concluded that MENK could exert antitumor effect through precisely regulating opioid receptor mediated functions of DCs. In addition, MENK treated DCs may serve as a new immunotherapy approach against tumor."

This is very exciting news. Lodonal is making great leaps and bounds paving the way for MENK. MENK said to be more effective than Lodonal and is now finally getting the recognition it deserves. Lodonal and MENK both work by decreasing tumors and modulating the immune system while increasing CD4 and CD8 counts. Please find the link here.